Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Palisade Bio, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 25 | 26 | +1 |
| Shares | 879.5K | 971.5K | +92.1K (+10.5%) |
| Value | $930.0K | $395.0K | −$535.0K (−57.5%) |
New holders (5)
Institutions that held Palisade Bio, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Private Advisor Group, LLC | 33,500 | $14.0K | 0.00% |
| First American Trust, FSB | 20,392 | $8.00K | 0.00% |
| Millennium Management LLC | 18,973 | $8.00K | 0.00% |
| Buckingham Strategic Wealth, LLC | 11,000 | $4.00K | 0.00% |
| Credit Suisse AG | 3 | $0 | 0.00% |
Sold out (4)
Institutions that held Palisade Bio, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Citadel Advisors LLC | 69,842 | $74.0K |
| Jane Street Group, LLC | 36,223 | $38.0K |
| Two Sigma Investments, LP | 21,560 | $23.0K |
| JPMorgan Chase & Co | 983 | $1.00K |